Ying Cheng1, Xiao-Qing Liu2, Yun Fan3, Yun-Peng Liu4, Yi Liu5, Ying Liu1, Li-Xia Ma1, Xian-Hong Liu1, Hui Li1, Hui-Zheng Bao1, Jing-Jing Liu1, Shuang Zhang1, Chun-Jiao Wu1. 1. Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China. 2. Department of Pulmonary Oncology, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China. 3. Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. 4. Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. 5. Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China.
Abstract
AIMS: As data on the use of circulating tumor cells (CTCs) to predict patient outcomes in extensive-stage small-cell lung cancer (ES-SCLC) remain inconclusive, we investigated the clinical value of CTC determination in an open-label, multicenter study of 91 patients with newly diagnosed ES-SCLC. MATERIALS & METHODS: Blood CTC counts were determined using the CellSearch® system at baseline, after the second cycle of chemotherapy, and on disease progression. RESULTS & CONCLUSION: Following the second cycle of treatment, CTC numbers and the change in CTCs were strong, significant and independent indicators for both progression-free survival and overall survival in ES-SCLC. The CTC change was associated with both refractory disease (response to initial therapy ≤3 months) and sensitive disease (response to initial therapy >3 months).
AIMS: As data on the use of circulating tumor cells (CTCs) to predict patient outcomes in extensive-stage small-cell lung cancer (ES-SCLC) remain inconclusive, we investigated the clinical value of CTC determination in an open-label, multicenter study of 91 patients with newly diagnosed ES-SCLC. MATERIALS & METHODS: Blood CTC counts were determined using the CellSearch® system at baseline, after the second cycle of chemotherapy, and on disease progression. RESULTS & CONCLUSION: Following the second cycle of treatment, CTC numbers and the change in CTCs were strong, significant and independent indicators for both progression-free survival and overall survival in ES-SCLC. The CTC change was associated with both refractory disease (response to initial therapy ≤3 months) and sensitive disease (response to initial therapy >3 months).
Entities:
Keywords:
circulating tumor cells; prognosis; small-cell lung cancer
Authors: Victoria Foy; Colin R Lindsay; Alexandra Carmel; Fabiola Fernandez-Gutierrez; Matthew G Krebs; Lynsey Priest; Mathew Carter; Harry J M Groen; T Jeroen N Hiltermann; Antonella de Luca; Francoise Farace; Benjamin Besse; Leon Terstappen; Elisabetta Rossi; Alessandro Morabito; Francesco Perrone; Andrew Renehan; Corinne Faivre-Finn; Nicola Normanno; Caroline Dive; Fiona Blackhall; Stefan Michiels Journal: Transl Lung Cancer Res Date: 2021-04
Authors: Ravi Salgia; R Waide Weaver; Michael McCleod; John R Stille; S Betty Yan; Stephanie Roberson; John Polzer; Amy Flynt; Eyas Raddad; Victoria L Peek; Sameera R Wijayawardana; Suzane L Um; Steve Gross; Mark C Connelly; Carrie Morano; Madeline Repollet; Renouard Sanders; Kurt Baeten; David D'Haese; David R Spigel Journal: Invest New Drugs Date: 2017-03-15 Impact factor: 3.850
Authors: Eva Obermayr; Christiane Agreiter; Eva Schuster; Hannah Fabikan; Christoph Weinlinger; Katarina Baluchova; Gerhard Hamilton; Maximilian Hochmair; Robert Zeillinger Journal: Cells Date: 2019-08-13 Impact factor: 6.600